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BACKGROUND: In advanced ovarian cancer, maximal efforts have to be attemptedto achieve optimal cytoreduction, as this represents
the keystone in the therapeutic management. This large, prospective study aims at investigating the role of computed tomography
(CT) scan in predicting the feasibility of optimal cytoreduction in ovarian cancer.
METHODS: A total of 195 consecutive patients with clinical/radiographic suspicion of advanced ovarian/peritoneal cancer were enrolled
at the Gynecologic Oncology Unit, Catholic University of Rome and Campobasso, Italy. Preoperative CT scans were performed with
a high-speed scanner (CT Hi Speed Nx/i Pro; 2-slice; GE Medical System). All patients underwent standard laparotomy, and maximal
surgical effort was attempted. The following CT parameters were used: peritoneal thickening, peritoneal implants 42cm, bowel
mesentery involvement, omental cake, pelvic sidewall involvement and/or hydroureter, suprarenal aortic lymph nodes 41cm,
infrarenal aortic lymph nodes 42cm, superficial liver metastases 42cm and/or intraparenchimal liver metastases any size, large
volume ascites (4500ml). Clinical data included were age, Ca125 serum levels, and ECOG-PS. Radiographic and clinical features
exhibiting a specificity 475%, a positive and negative predictive value 450%, an accuracy 460% in predicting surgical outcome were
assigned a point value of 2. With this scoring system, a predictive index (PI) was calculated for each patient.
RESULTS: The PI scores ranged from 0 to 6, and from 0 to 8, in Model 1 (including only radiographic parameters) and in Model 2
(including radiographic and clinical data). The AUC was 0.78þ0.035 in Model 1, and 0.81þ0.031 in Model 2. Therefore, the
addition of ECOG-PS data led to the improvement of the diagnostic performances (z¼2.41, P-value o0.05).
CONCLUSIONS: Computed scan still represents a valid tool to predict ovarian cancer optimal cytoreduction; the predictive ability of a
CT scan-based model is improved by integrating ECOG-PS data.
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Even in the absence of randomized trials supporting the role of
cytoreductive surgery in the treatment of advanced ovarian cancer,
there is a general consensus regarding the need to pursue the
achievement of the minimal amount, or even the absence of visible
residual tumour at primary surgery, given its direct relation with
prolonged survival time (Hunter et al, 1992; Bristow et al, 2002;
Eisenkop et al, 2006).
Although the term ‘optimal’ has been applied over time to
cytoreductive surgery achieving a maximal diameter of residual
tumour from 0 to even 3cm (Nickles Fader and Rose, 2007),
the GOG currently defines as ‘optimal’ a residual disease p1cm;
indeed, the evolution of this definition to include patients
undergoing cytoreduction to no apparent disease is reasonably
going to rapidly occur (Bristow et al, 2002). Therefore, while
awaiting for the mature results of the EORTC 55971 phase III
randomized trial comparing upfront debulking vs secondary
cytoreduction after neo-adjuvant chemotherapy in stage IIIC/IV
ovarian cancer (Vergote et al, 2008), maximal efforts have to be
attempted to leave no residual tumour at primary surgery, as this
commitment represents the keystone in the management of
advanced disease.
In this context, much attention has been focused on laboratory
assay, clinical and radiographic parameters, or, more recently,
laparoscopically assessed scores (Fagotti et al, 2006, 2008; Brun
et al, 2008) able to preoperatively define each patient’s chance to
undergo optimal cytoreduction. Although the accuracy of pre-
operative serum Ca125 levels ranges between 50 and 78%, and
conflicting data about the predictive ability of Ca125 levels
have been reported (Chi et al, 2000, 2009; Cooper et al, 2002;
Saygili et al,2 0 0 2 ;M e m a r z a d e het al, 2003), computed tomography
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s(CT) scan assessed parameters might conceivably offer better
predictive performances, as they define not only the extension of
disease, but also more important, the involvement of specific intra-
abdominal sites generally recognised to heavily preclude the
feasibility of optimal debulking, such as portal triad disease,
agglutinated bowel/mesentery, bulky diaphragmatic disease, or
suprarenal aortic lymph nodes (Eisenkop and Spirtos, 2001). In
particular, Bristow et al (2000) developed a CT scan-based model
achieving an overall accuracy of 93% in predicting successful
cytoreduction. However, the recent demonstration that CT pre-
dictors are not reliably reproducible in series different from the
one(s) upon which the model was originated has questioned the true
role of CT scan in predicting surgical outcome outside each own
institution (Axtell et al, 2007). Additional sources of concern about
the usefulness of CT imaging predictors are represented by the small
size of previously published cohorts, often including early-stage
cases, their retrospective nature, and heterogeneity of imaging
procedures across institutions, as well as combinations of different
CT predictors (Nelson et al, 1993; Forstner et al, 1995; Meyer et al,
1995; Bristow et al, 2000; Byrom et al, 2002; Dowdy et al, 2004;
Qayyum et al, 2005; Axtell et al,2 0 0 7 ) .
Moreover, discrepancies across the studies and reliability of
the results are also conceivably related to the time frame,
and duration of accrual as variations and/or improvements in
the imaging techniques, equipment, and performances have
occurred over time, and also diverge across different imaging
centres.
The aim of this study was to investigate the overall performance
of CT in predicting the feasibility of primary optimal cyto-
reduction in advanced ovarian cancer patients in a large,
prospective trial. The performances of different predictive
models, including also clinically assessed parameters, have been
considered.
MATERIALS AND METHODS
Between January 2005 and October 2008, 195 consecutive patients
with clinical and radiographic suspicion of advanced (Stage
III–IV) ovarian/peritoneal cancer were consecutively enrolled at
the Gynecologic Oncology Unit, Catholic University of Rome and
Campobasso, Italy.
Routinary staging work up included complete physical and
gynaecological examination, Ca125 serum level assessment, chest
X-rays, and abdomino-pelvic CT scan. ECOG performance status
(ECOG-PS) was also recorded. To select advanced stage cases,
clinical and radiological parameters were used as the presence of at
least two of the following criteria: ascites (4500ml), CT evidence
of metastatic disease, and elevated Ca125 levels (4500IUml
 1).
Exclusion criteria were represented by ECOG-PS 42, large
volume extra-abdominal disease.
At time of study conception and design (2004), the approval of
the Institutional Review Board was not required because the study
did not include diagnostic or therapeutic procedures different
from the standard ones (preoperative staging and cytoreductive
surgery).
Imaging technique
Preoperative CT scans were performed with a high-speed scanner
(CT Hi Speed Nx/i Pro; 2-slice; GE Medical System, Milwaukee,
WI, USA). Computed tomography examinations were obtained
after the oral administration of 1000ml of diluted iodinated
water soluble contrast medium (approximately 2% Gastrografin
solution; 20ml Gastrografin/1000ml water). All CT scans
were acquired at baseline and 70s after i.v. administration of
120–130ml high-concentration non-ionic iodinated contrast
medium (350–370mgIml
 1). The usual flow rate was 3mls
 1.
Images were obtained in a craniocaudal direction, from
diaphragm to the ischial tuberosities, with 5mm thickness and
15mms
 1 table speed. The hard copy images were reviewed by
two radiologists (GS, EC) with a special interest in gynaecologic
oncology imaging, who were unaware of the clinical characteristics
of the patients. In case of disagreement a re-joint evaluation of the
scans was performed until a consensus was reached.
Surgical procedures
All patients underwent standard longitudinal laparotomy, and
intensive surgical staging was attempted according to the standard
guidelines. Maximal surgical effort (achievement of o1cmresidual
disease) has been attempted in all patients, and when possible,
included surgical removal of tumour masses, along with total
abdominal hysterectomy, bilateral salpingo-oophorectomy, radical
omentectomy, appendectomy, multiple biopsies, and additional
surgery (intestinal resections (20%), diaphragm stripping (20%),
abdomino-pelvic peritoneal stripping (35%), liver and pancreatic
resection (9%), splenectomy (15%), if required. Radical pelvic and
para-aortic lymphadenectomy was performed in all patients under-
going primary cytoreduction leaving a residual tumour p1cm.In
case of impossibility to proceed to primary optimal cytoreduction,
as assessed at primary laparotomic effort, patients were triaged to
neoadjuvant chemotherapy (Fanfani et al, 2003; Vergote et al, 2005).
Data analysis
The computed tomography parameters used in the data analysis
were as follows: peritoneal thickening (diffuse, linear, 41cm
thickening) or peritoneal implants 42cm, bowel mesentery
involvement, omental extension (spleen, stomach, lesser sac),
pelvic sidewall involvement and/or hydroureter, suprarenal aortic
lymph nodes 41cm, infrarenal-aortic lymph nodes 42cm,
superficial liver metastases 42cm and/or intraparenchimal liver
metastases any size, large volume ascites (4500ml).
Clinical data used in the analysis were age, Ca125 serum levels,
and ECOG-PS. For the purpose of the study, analysis of the data
was performed by two different approaches: in Approach A, the
sensitivity, specificity, negative predictive value (NPV), positive
predictive value (PPV), and accuracy of each radiographic
parameters, as well as clinical features in predicting surgical
outcome were calculated. Sensitivity was defined as the number
of correctly defined suboptimally debulked cases (true positives)
divided by the total number of suboptimally cytoreduced patients.
Specificity was defined as the number of correctly defined
optimally debulked cases (true negatives) divided by the total
number of optimally cytoreduced patients.
NPV corresponded to the number of true negatives divided
by the total number of negative results for each parameter, and
PPV corresponded to the number of true positives divided by the
total number of positive results for each parameter. Accuracy was
calculated as the sum of true positives and true negatives divided
by the total number of patients in the study.
Inclusion of a specific radiographic parameter in the final model
required a specificity X75%, a PPV X50%, and a NPVX50%: the
radiographic feature satisfying these three criteria was assigned a
point value of 1 (Bristow et al, 2000). An additional point was
assigned to those parameters that, besides the above criteria, also
showed an overall accuracy X60% in predicting surgical outcome.
With this scoring system, a predictive index (PI) was calculated for
each patient.
In Approach B, the w
2-test or Fisher’s exact test for proportion
were performed for each radiographic and clinical parameter, and
all features showing a statistically significant association (P-value
o0.05) with surgical outcome were analysed by means of logistic
regression (Cox, 1970) using a stepwise routine. Features shown to
maintain the association with surgical outcome in multivariate
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sanalysis were used to generate a predictive model. In particular,
a PI score was assigned to each patient according to the absence
or presence of any of the variables identified. The predictive
performances of the PI scores in approaches A and B were
tabulated in different categories, and receiver operating
characteristic (ROC) curves were obtained to analyse the ability
of different PI models in predicting surgical outcome. The
statistical significance of differences between ROC estimates was
performed applying the method by Hanley and McNeil (1982).
Finally, the pre-test probability, likelihood ratios, and post-test
probability of models deriving from Approaches A and B were
calculated to assess their efficacy in predicting surgical outcome
(Deeks and Altman, 2004).
RESULTS
At the end of enrolment, the final study included 195 patients
consecutively seen at the Division of Gynecologic Oncology of
the Catholic University of Rome and Campobasso; patients’
characteristics at initial diagnosis as well as their surgical outcome,
and final pathology are summarised in Table 1. Median age was
59 years (range: 31–85), with 69 (35.4%) of cases aged X65 years;
approximately 25% of patients had ECOG-PS¼2. Overall, the rate
of cytoreduction to absent or p1cm residual disease were 27.2 and
16.9%, respectively, for an overall proportion of optimal cyto-
reduction of 44.1%. One hundred seventy-four (89.2%) were
diagnosed as having primary ovarian carcinoma, whereas 19 cases
(9.7%) were metastatic tumours from other primary tumours,
thus emphasising the need to proceed always to the histological
assessment of pathology. Because of the prospective nature of the
study, results refer to the whole study population. One hundred
forty-five patients (74.4%) had CA125 serum levels 4500IUml
 1.
Neither was there any difference in the percentage of optimal
cytoreduction over time of enrolment, nor across the six operating
teams (data not shown).
Imaging findings
The features assessed on CT scan were prospectively recorded
in the data form presented in Table 2. In the same Table the
diagnostic performances of each radiographic parameter compared
with laparotomic findings are summarised: in terms of specificity,
the best performance was documented for infrarenal aortic lymph
nodes and omental extension, whereas very low specificity rates
were documented for peritoneal thickening and ascites. Overall, the
accuracy rate ranges between 40.2 (pelvic involvement) and 81.9%
(involvement of infrarenal aortic lymph nodes).
Approach A
According to the Bristow criteria, two radiographic parameters
(omental extension, liver involvement) fulfilled the criteria
required for being assigned a point value¼1, while the involve-
ment of diaphragm or bowel mesentery, and, among clinical
parameters, ECOG-PS obtained a point value of 2 (Table 3). On the
basis of the absence or presence of the above cited parameters a PI
score was calculated for each patient; the frequency distribution of
the predictive score in the overall series are presented in Figure 1.
In particular, the PI scores range from 0 to 6 (median¼2) and
from 0 to 8 (median¼2) in Model 1 (not including ECOG-PS data)
and in Model 2 (including ECOG-PS data), respectively. The
calculation of sensitivity, and specificity was carried out for each
PI score X1 to the upper limit in each model, and the ROC curve
analysis was performed. The AUC was 0.78±0.035 in Model 1, and
0.81±0.031 in Model 2.
The addition of ECOG-PS data led to the improvement of the
diagnostic performances, as the difference between the AUCs of Model
1 and Model 2 was statistically significant (z¼2.41, P-value o0.05).
Approach B
Univariate and multivariate analysis were carried out to analyse
radiographic and clinical features for their association with
surgical outcome (Table 4). All radiographic parameters but one
Table 1 Characteristics of the patients enrolled
Characteristics No. of patients (%)
All cases 195
Age (years)
p65 126 (64.6)
465 69 (35.4)
ECOG-PS
0–1 146 (74.9)
2 49 (25.1)
Residual tumour
Absent 53 (27.2)
p1cm 33 (16.9)
41cm 109 (55.9)
Final pathology
Ovarian cancer 174 (89.2)
Synchronous tumour (endometrial, breast) 2 (1.0)
Other primary
a 19 (9.7)
FIGO stage
b
IIIB 17 (8.7)
IIIC 142 (72.8)
IV 36 (18.4)
Ca125 levels (IUml
 1)
p500 50 (25.6)
4500 145 (74.4)
aSarcoma (n¼5), stomach (n¼4), colorectal (n¼4), endometrial (n¼3), breast
(n¼2), lymphoma (n¼1).
bOnly ovarian cancer.
Table 2 Accuracy, negative, and positive predictive value of computed tomography scan assessed parameters vs laparotomic findings
Specificity NPV PPV Accuracy
Peritoneal thickening, peritoneal implants 42cm 47.5 48.7 86.2 78.5
Bowel mesentery involvement 69.6 83.3 61.1 72.6
Omental extension (spleen, stomach, lesser sac) 87.0 87.6 42.8 79.2
Pelvic sidewall involvement and/or hydroureter 81.0 30.9 73.8 40.2
Suprarenal aortic lymphnodes 41cm 85.9 75.3 50.0 70.3
Infrarenal-aortic lymphnodes 42cm 91.8 86.6 50.0 81.9
Superficial liver metastases 42cm and/or intraparenchimal liver metastases any size 80.9 85.6 46.1 74.9
Large volume ascites (4500ml) 55.7 84.5 70.9 75.0
Diaphragmatic disease (widespread infiltrating carcinomatosis, or confluent nodules) 90.7 46.2 93.9 67.0
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s(pelvic involvement) were shown to be predictive of residual
disease in univariate analysis, and were therefore included in the
multivariate analysis.
Among clinical parameters, only ECOG-PS was associated with
the extent of primary cytoreduction. In multivariate analysis, only
involvement of peritoneum, bowel mesentery, suprarenal aortic
lymph nodes, and diaphragm, as well as ECOG-PS maintained
their independent association with surgical outcome, and were
assigned 1 point value. The PI score therefore ranged from
0 (absence of all selected radiographic features) to 4 (presence of
all selected radiographic features) in Model 3, and from 0 to 5 in
Model 4, which included selected radiographic variables plus
ECOG-PS. Figure 2 shows the distribution of PI scores in Models 3
and 4. The calculation of sensitivity and specificity was carried out
for each PI score X1 to the upper limit in each model, and the
ROC curve analysis was performed. The AUC was 0.78±0.034 in
Model 3, and 0.82±0.031 in Model 4. In this case, also the addition
of ECOG-PS data produced a more favourable AUC for Model 4
(z¼3.41, P-value o0.05).
The pre-test probability, likelihood ratio, and the post-test
probability were calculated for Models 2 and 4 at different cutoff
values (Table 5). The pre-test probability was 55.8% (109 patients
with residual tumour 41cm at primary cytoreductive effort).
There was an increasing improvement of the post-test prob-
ability paralleling the increase in the cutoff values for both Models
2 and 4: indeed in Model 2, 27 cases had a PI score 45, and 25 of
them had suboptimal cytoreduction; the positive likelihood ratio
was 9.86, and the post-test probability was 92.6% with an
improvement of 36.8% compared with the pre-test probability.
Similarly, in Model 4, 28 cases had a PI score 43, and 26 of
them had suboptimal cytoreduction; the positive likelihood
ratio was 10.25, and the post-test probability was 92.8% with an
improvement of 37.0% compared with the pre-test probability.
To take advantage of a ‘easy handling’ PI score, practically, the
rate of inappropriate unexploration, which therefore should tend
to 0, can be easily calculated as the inverse of PPV, whereas the
proportion of unnecessary exploration corresponds to the inverse
of NPV. In our series, only Models 2 and 4 (both including
radiographic features and ECOG-PS data) provided PPVs¼100%
at PI score cutoff values of 7 and 4, respectively (Tables 6 and 7).
DISCUSSION
This is the first study reporting the results from a very large,
prospective trial investigating the role of CT scan-based evaluation
in the preoperative prediction of optimal cytoreduction in
advanced ovarian cancer. We developed predictive models from
two different approaches (on the basis of either on diagnostic
performance of each CT-derived parameter, or on results from
multivariate analysis), which also took significant clinical variables
into account: in both approaches ECOG-PS resulted the only
clinical variable fulfilling the criteria required for inclusion in the
predictive models, whereas preoperative Ca125 serum levels and
age showed a low degree of accuracy in predicting surgical
outcome. Indeed, the predictive models, including ECOG-PS data,
were more accurate than those derived from CT alone; these
Table 3 Prediction of optimal cytoreduction: computed tomography-based and clinically assessed parameters assigned a point value according to Bristow
criteria (Approach A)
Specificity NPV PPV Accuracy Point
Radiographic
Peritoneal thickening, peritoneal implants 42cm 34.5 74.3 63.8 65.9 0
Bowel mesentery involvement 75.4 61.8 73.6 67.5 2
Omental extension (spleen, stomach, lesser sac) 92.9 50.4 82.8 56.2 1
Pelvic sidewall involvement and/or hydroureter 80.2 45.6 59.5 48.7 0
Suprarenal aortic lymph nodes 41cm 86.0 47.7 70.0 52.3 0
Infrarenal aortic lymph nodes 42cm 94.2 48.5 82.1 53.3 0
Superficial liver metastases 42cm and/or intraparenchimal liver metastases any size 83.5 51.1 73.1 57.1 1
Large volume ascites (4500ml) 40.7 60.3 62.2 61.6 0
Diaphragmatic disease (widespread infiltrating carcinomasis, or confluent nodules) 77.6 61.1 76.8 67.8 2
Clinical
Age, years (p65 vs 465) 73.2 48.4 64.6 53.1 0
Ca125 levels, IUml
 1 (p500 vs 4500) 25.8 44.8 55.9 53.3 0
ECOG-PS (0–1 vs 2) 91.9 54.1 85.7 62.0 2
Statistically significant values have been indicated as bold values.
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Figure 1 Distribution of predictive index values (A) and ROC curves
(B) in Model 1 and Model 2.
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sfindings confirm previously reported results (Bristow et al, 2000;
Chi et al, 2000; Cooper et al, 2002; Saygili et al, 2002; Memarzadeh
et al, 2003), and definitively recognise the extent of the impact
played by ECOG-PS in the preoperative prediction of ovarian
cancer primary resectability (Aletti et al, 2007). The models based
on diagnostic performance and on results from multivariate
analysis showed the same accuracy in predicting the chance of
optimal cytoreduction, although they included slightly different
CT-based features; in particular, involvement of bowel mesentery,
omentum, liver, and diaphragm were shown to fulfil all the
required criteria (Bristow et al, 2000) in Approach A, whereas in
multivariate analysis the involvement of peritoneum and suprar-
enal aortic lymph nodes, besides bowel/mesentery and diaphragm
disease, were independently associated with suboptimal cyto-
reduction. The divergence between the two approaches remains
difficult to explain, although the strict and, to a certain extent,
unpredictable associations among the variables might more likely
have an impact on multivariate analysis. In any case, our findings
support the relevance of the assessment of the status of bowel
mesentery and diaphragm involvement, recognised among the
most important features determining the feasibility of ovarian
Table 4 Prediction of optimal cytoreduction: univariate and multivariate analysis by logistic regression of CT-based and clinically assessed parameters to
use for modeling (Approach B)
Univariate Multivariate
v
2 P-value v
2 P-value Point
a
Radiographic
Peritoneal thickening, peritoneal implants 42cm 16.34 0.0001 3.45 0.063 1
Bowel mesentery involvement 17.50 0.0001 5.35 0.0207 1
Omental extension (spleen, stomach, lesser sac) 11.13 0.0008 2.52 0.11 0
Pelvic sidewall involvement and/or hydroureter 2.28 0.13 —— 0
Suprarenal aortic lymph nodes 41cm 4.21 0.040 4.36 0.036 1
Infrarenal aortic lymph nodes 42cm 8.15 0.0043 — — 0
Superficial liver metastases 42cm and/or intraparenchimal liver metastases any size 8.58 0.0034 — — 0
Large volume ascites (4500ml) 8.15 0.0043 — — 0
Diaphragmatic disease (widespread infiltrating carcinomasis, or confluent nodules) 25.35 0.0001 7.13 0.0076 1
Clinical
Age, years (p65 vs 465) 2.51 0.08 —— 0
Ca125 levels (p500 vs 4500IUml
 1) 2.98 0.11 —— 0
ECOG-PS (0,1 vs 2) 19.71 0.0001 14.22 0.0002 1
aOnly variable achieving a P–value o0.10 were assigned a point value. Statistically significant values have been indicated as bold values.
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Figure 2 Distribution of predictive index values (A) and ROC curves
(B) in Model 3 and Model 4.
Table 5 Pre-test probability, likelihood ratio, and post-test probability for
different predictive models of primary optimal cytoreduction in ovarian
cancer
Test Cutoff
Pre-test
probability
Positive
likelihood ratio
Post-test
probability
Model 2 5 55.8 9.86 92.6
Model 4 3 55.8 10.25 92.8
Table 6 Performance of Approach A (Model 2) in defining the rate of
patients unnecessarily explored or inappropriately unexplored
Model 2
PIV
Unnecessarily explored
(1 NPV) (%)
Inappropriately unexplored
(1 PPV) (%)
0 17.9 28.8
1 25.0 27.6
2 33.3 19.4
3 39.0 18.2
4 48.1 16.3
5 50.0 7.4
6 53.6 5.0
7 54.3 0
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scancer cytoreduction (Bristow et al, 2000; Axtell et al, 2007).
Although the results obtained using the two approaches were
similar, we think that the approach based on diagnostic
performances of CT parameters plus ECOG-PS is more easily
understandable and manageable, and is therefore recommended
for future studies and/or use.
A direct comparison of our results with those reported in the
literature is rather difficult; indeed, the vast majority of previously
published studies investigated relatively small sample series and,
given their retrospective design, were likely characterized by a
selection bias (Table 8). Moreover, the number of CT-assessed
parameters used in the prediction of surgical outcome showed a
wide range of variability across different studies (Nelson et al,
1993; Forstner et al, 1995; Meyer et al, 1995; Bristow et al, 2000;
Byrom et al, 2002; Dowdy et al, 2004; Qayyum et al, 2005; Axtell
et al, 2007) and, more important, the use of a CT-based cutoff
score was investigated only by three Institutions (Nelson et al,
1993; Forstner et al, 1995; Eisenkop and Spirtos, 2001). None-
theless, there is a general consensus that CT scan represents a valid
tool to address the issue of preoperative prediction of ovarian
cancer resectability at primary surgery.
Some issues, however, have to be discussed: first, although it can
be argued that the percentage of optimal cytoreduction in our series
was not so close to the upper limit of the range reported in the
literature (Nickles Fader and Rose, 2007), it has to be taken into
account that our patients were selected on the basis of clinical and
radiographic features of very advanced disease, thus resulting in
91.3% FIGO stage IIIC/IV cases, whereas other series also included
FIGO stage I/II patients in a range between 19 and 45% (Nelson
et al, 1993; Forstner et al, 1995; Meyer et al, 1995; Byrom et al, 2002;
Qayyum et al, 2005). We recognise that the predictive performance
of any test is expected to loose a part of its potential advantages with
an increasing rate of optimal cytoreduction. Although this remains
to be experimentally tested, on the other hand it cannot be excluded
that changes in the percentage of optimal cytoreduction across
different centres could more likely result in the modification of the
threshold level of the PI cutoff value, rather than in questioning the
overall PIV-based approach. Moreover, it has to be acknowledged
that very high percentages of optimal cytoreduction are hardly
achievable outside a few, very committed Institutions; in this
context, the availability of a tool suitable to adapt to the range of the
most commonly achievable rates of optimal cytoreduction is
clinically relevant (Wakabayashi et al,2 0 0 8 ) .
We developed predictive models able to produce different PI
values, thus providing the chance to choose the most adequate
cutoff on the basis of patients’ and disease characteristics
Table 7 Performances of Approach B (Model 4) in defining the rate of
patients unnecessarily explored or inappropriately unexplored
Model 4
PIV
Unnecessarily explored
(1 NPV) (%)
Inappropriately unexplored
(1 PPV) (%)
0 8.0 37.1
1 25.4 22.6
2 36.3 18.3
3 49.7 7.2
4 54.7 0
Table 8 Summary of the studies analysing the performance of computed tomography (CT) scan in the prediction of optimal cytoreduction in ovarian
cancer
Author,
year Time
Type of
study No.
% Stage
III/IV
No. of
surgeons
Optimal
RT (cm)
% Optimal
debulking
CT scan
slice
thickness
CT-based
factors
CT
score
Cutoff
score NPV PPV
Nelson et al (1993) December 1985 R 42 81 4 o26 9 N S 8
a No — 95.8 66.7
May 1991 93.8
b 66.7
b
Meyer et al (1995) 1989 R 28 57 3 p25 7 1 0 m m6
c Yes
c X3 76.2 100
1992 54.5
b 100
b
Forstner et al (1995) June 1990
May 1994
P4 3 7 2 N A p28 6 7 – 1 0 m m 9
d No — 92.5 100
Bristow et al (2000) July 1997
July 1999
R 41 100 9 p14 95 m m 1 3
e Yes X4 100 87.5
Byrom et al (2002) January 1998
August 1999
R7 7
f 55 NA 0 36
g 8–10mm 2
h Yes
i 5
i 90 95
Dowdy et al (2004) 1996
2001
R 87 100 NA o17 1 5 – 1 0 m m 3
j No — 81
j 79
j
Qayyum et al (2005) NA R 105 77 3 p28 0 7 – 1 0 m m 1 5
k No — 96 94
Axtell et al (2007) 1999
2005
R 67 100 NA p17 8 5 – 1 0 m m 1 4
l No — 98 46
Abbreviations: NA¼not applicable; NS¼not specified; P¼prospective; R¼retrospective.
aCT-assessed criteria for unresectability were as follows: (1) the attachment of
omentum to spleen; (2) the presence of 42cm disease located at any one or more of the following sites: mesentery, gallbladder fossa, pericardiac lymph nodes, pulmonary or
pleural nodules, liver surface or parenchyma, suprarenal para-aortic nodes, diaphragm.
bIn stage III/IV cases.
cScores from 0 to 2 were assigned for the presence of disease at the
following sites: omentum, liver, para-aortic nodes, diaphragm and lung base, small bowel mesentery, amount of ascites, according to the diameter and extension of the disease.
dThe following parameters were used: 42cm disease located at peritoneum (thickening or implant), at small or larger bowel mesentery, omentum, pelvis (sidewall, parametria,
hydroureter), infrarenal or suprarenal nodes, liver (surface or parenchyma), porta hepatis/gallbladder, diaphragm/lung base, inguinal canal, ascites.
eThe following parameters were
used: 42cm disease located at mesentery, porta hepatis, lesser sac, intersegmental fissure, dome of the liver, gastrosplenic ligament, diaphragm, nodes at and above the celiac
axis, presacral extraperitoneal disease.
fIncluding also benign (n¼26), and early-stage cancer (n¼23).
g36% in the whole series (52 out of 77), and 10.7% in stage III–IV cancer
(3 out of 28).
hOnly CT-assessed omental cake and presence of mesenteric disease were independent predictors of unresectability;
iThe score also included age and Ca125
levels.
jMultivariate analysis identified three variables (diffuse peritoneal carcinomatosis, ascites, and diaphragm involvement) as the only significant predictors of unresectability;
NPV and PPV refer to the model including these three parameters.
kCT-assessed criteria for unresectability were as follows: presence of 42cm disease located at any one or
more of 14 critical sites: porta hepatis, intersegmental fissure, gallbladder fossa, subphrenic space, gastrohepatic and gastrosplenic ligaments, lesser sac, small bowel mesentery,
dome of the liver surface, suprarenal para-aortic nodes, celiac axis supradiaphragmatic involvement, liver, abdominal wall invasion.
lMultivariate analysis including 14 CT-based
variables and four clinical parameters identified only two variables (tumour42cm at the large bowel mesentery and diaphragm) as the only significant predictors of
unresectability; NPV and PPV refer to the model including these two parameters.
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s(performance status, need to perform very extensive surgery),
and surgeon’s commitment: obviously, the predictive performance
of any model varies with the chosen cutoff value of PI; for
instance, if we had used a PI value of 2 (see Table 6, Model 2), we
would have obtained a rate of unnecessary exploration of 33.3%,
in face of a rate of inappropriate unexploration of 19.4%, which
means that almost one-fifth of our patients would have been
deprived of the potential survival benefits achievable with optimal
cytoreductive surgery.In this context, the need to use a PI with
the highest degree of accuracy in minimising the rate of cases
erroneously judged to have an unresectable disease is of utmost
important, and is even more relevant than running the risk of
unnecessarily explore patients who rather present unresectable
disease at laparotomy. Therefore, as a practical rule, the
calculation of the rate of inappropriate unexploration can be
carried out from our models, as the inverse of PPV and therefore
will be 0% at the cutoff values of 7 and 4, in Models 2 and 4,
respectively. Finally, more sophisticated imaging approaches
such as Positron emission tomography/computed tomography
(PET/CT) (Risum et al, 2008), as well as laparoscopic approaches
(LPS) scores (Fagotti et al, 2006, 2008; Brun et al, 2008) have
been recently investigated in terms of prediction of surgical
outcome in advanced ovarian cancer, whereas the results of
PET/CT seem currently too preliminary to draw any definitive
conclusion, data from pilot and prospective studies proposed
open LPS as a reliable and flexible predictive tool scores
(Fagotti et al, 2006, 2008; Brun et al, 2008). Although the accuracy
of LPS in the assessment of specific sites of disease involvement
is expectedly higher compared with CT scan (Fagotti et al, 2006,
2008; Brun et al, 2008), the clinical impact of whether triaging or
not advanced ovarian cancer patients to laparotomy on the basis
of LPS findings urgently requires to be investigated in controlled
clinical trials.
In conclusion, we showed that CT scan still represents a valid
tool into address the issue of preoperative prediction of ovarian
cancer resectability at primary surgery, and that its predictive
performances might be improved by the inclusion of ECOG-PS
data. As already acknowledged (Bristow et al, 2000; Cooper et al,
2002), a multi-institutional prospective trial hopefully integrating
preoperative clinical and radiographic variables is required to test
whether the predictive models maintain their accuracy when
applied to different patient cohorts. Indeed, a very recently
published study by Gemer et al (2009) has underscored the
difficulty to devise generally applicable models able to reliably
predict surgical outcome in advanced ovarian cancer patients,
across different Institutions. This issue can become clinically more
relevant in the light of the upcoming mature results from EORTC
55971 trial.
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